Two Sigma Securities’s KALA BIO KALA Stock Holding History

Two Sigma Securities’s Portfolio KALA Stock Details KALA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-262	Closed	-$7.29K	–	1927
2025 Q4	$7.29K	Buy	+262	New	+$11.7K	﹤0.01%	1319
2023 Q1	–	Sell	-130	Closed	-$249K	–	2975
2022 Q4	$249K	Buy	+130	New	+$51.5K	0.01%	1725
2022 Q2	–	Sell	-7	Closed	-$23K	–	2557
2022 Q1	$23K	Sell	7 -8	-53%	-$21K	﹤0.01%	1959
2021 Q4	$44K	Buy	+15	New	+$69.6K	﹤0.01%	1292

Other funds holding KALA

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Two Sigma Securities's KALA Position: Q1 2026 in Review

Two Sigma Securities sold out of KALA BIO (KALA) in Q1 2026, closing a stake of 262 shares — an estimated $7.29K sold.

Two Sigma Securities first reported a position in KALA in Q4 2021 and held it in 4 quarters. The position peaked at $249K in Q4 2022. 28 funds tracked by Wall St. Rank hold KALA as of Q1 2026.

Two Sigma Securities reported no remaining KALA BIO position as of Q1 2026 after selling out during the quarter.
Two Sigma Securities sold 262 KALA BIO shares in Q1 2026, an estimated $7.29K.
Two Sigma Securities first reported a position in KALA BIO in Q4 2021 and held it in 4 quarters.
Two Sigma Securities's KALA BIO position peaked at $249K in Q4 2022.
28 funds tracked by Wall St. Rank held KALA BIO as of Q1 2026.

Based on Two Sigma Securities's 13F filing for Q1 2026, filed 15 May 2026.